reason report
pivot success atop dermat amidst high expect pt
bottom line morn mp announc posit
top-line result topic jakafi phase trial
atop dermat ad top-line result demonstr significantli
patient treat topic jakafi twice daili
bid dose achiev primari endpoint signific improv
investig global assess treatment success iga-t vs
placebo week compani disclos overal efficaci
safeti profil topic jakafi consist prior data
notabl new safeti issu remind phase trial
efficaci result show versu inert vehicl rate
topic jakafi bid dose pivot endpoint iga respons
week eadv data present
upcom scientif meet see success pivot trial
ad valid topic jakafi opportun dermatolog indic
believ expect trial posit fairli high
given result phase trial sampl size necessari
demonstr safeti indic second phase true-
trial on-going initi result also expect
result posit intend submit new drug applic nda
ruxolitinib cream expect dupix continu
achiev broad use moder sever ad market believ
topic jakafi meaning role ad believ could
prescrib prefer non-steroid option conjunct
system treatment base initi success updat
model increas probabl success prior
result new pt prior current estim
 launch topic jakafi peak revenu
account per share risk-adjust npv share
updat model reflect posit top-line result increas
pt base posit top-line result
trial increas probabl success topic jakafi
prior await initi result second phase
trial expect also modestli adjust
launch year revenu forecast reflect
time nda submiss anticip approv chang
result new pt prior view could decid
in-licens dermatolog asset pave way commerci launch
topic jakafi despit recent morphosi mor gy op deal see
note compani approxim cash balanc
net debt total capit
price-to-earnings lt ep growth
net debt total capit calcul use bv
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
rate corp share market perform commerci stage
biotechnolog compani develop drug modul pathway involv cell signal
oncolog autoimmun disord compani solid backbon revenu lead
asset jakafi oral inhibitor jak pathway estim worth per share
howev see compani execut goal diversifi revenu see stock
fulli valu favor upcom catalyst potenti competit fedratinib gener
eros anticip promis asset pipelin think
opportun alreadi larg reflect share howev share could repres
good invest investor longer term horizon beyond one year valuat
will invest mid-cap biotechnolog compani solid financi fundament
use risk-adjust sum-of-the-part methodolog valu examin clinic
regulatori commerci risk opportun individu indic region
assign probabl success account likelihood achiev
revenues/expens risk-adjust sum-of-the-part analysi appli discount rate
cash flow gener asset determin total net present valu
risk-adjust asset total npv reflect remain clinic regulatori risk
productpeak revenu mn phase developmentnpv mn probabl successrisk-adjust npv mn expect launchnet current value/sharejakafi polycythemia eu us ra eu ra ad indic inhibit fgfr fl mcl cmet ww jak atop jak us r/r regulatori eu r/r oncolog pipelinei ii asset share count total risk-adjust equiti valu risk residu non-deplet profitabilityincyt corpor mf/pvolumianticlusigjak jaktafasitamab dlbclearli oncolog pipelin te corpor
commerci risk competit compani develop treatment myelofibrosi
polycythemia vera therapeut area compet repres risk
clinic risk clinic trial failur incyt compound develop includ itacitinib
pemigatinib ruxolitinib compani earli stage pipelin repres risk
current valuat
regulatori risk even posit clinic data regulatori approv need market
prescript drug develop market regul may declin approv applic
incyt development-stag compound repres risk current valuat
companyprogram/drugtherapeut areaeventtimingev typetri phaseincytetop ruxolitinibatop dermatitisdata phiii trial topic ruxolitinib mild-moder trial dataphiiiincytepemigatinibcholangiocarcinomapotenti us approv cholangiocarcinoma may tafasitamabdiffus larg cell lymphoma submiss tafasitamab r/r dlbcl combin data inhibitor trial dataphiincytejakafimyelofibrosisproof-of-concept combin data pim inhibitor jakafi trial dataphiincytejakafiatop dermatitispotenti nda submiss topic non-smal cell lung cancerpotenti fda approv met-mut vs host diseasedata phiii trial steroid refractori chronic trial dataphiiiincyt tafasitamabdiffus larg cell lymphoma potenti us approv r/r lymphomapotenti data phii r/r trial dataphiiincyteparsaclisibmargin zone lymphomapotenti data phii r/r trial dataphiiincyteparsaclisibmantl cell lymphomapotenti data phii r/r trial datapiiincytepemigatinibbladd cancerdata phii trial pemigatinib metastat bladder cancer trial cancerdata phii trial r/r anal trial dataphiiincyteitacitinibgraft vs host diseasedata trial chronic trial dataphiiiincyt catalyst corpor
 mn except ep
product revenu
chang fair valu acquisition-rel conting consider
earn tax ebt
balanc sheet mn
compani report svb leerink estim
